shortcomings of the current allocation system, based on in/out criteria, is poor prognostic accuracy post-LT. (9, 10) Although several models have shown superior discrimination to MC, they failed to show enough potential in both accuracy and utility (simplicity, biological rationale, and inclusion of only preoperative factors) to replace MC in the national allocation system. (3) (4) (5) (6) Pretransplant locoregional therapy (LRT), namely bridging therapy, has been established as the treatment approach in all but the least competitive regions, with 60%-90% of LT candidates receiving LRT. (9, 10) Beyond its obvious utility to put a pause on increasing tumor burden and maintain candidates within MC, it also serves as a test of tumor biology. (13) Moreover, LRT has enabled us to downstage patients who were originally MC-out to MC-in. Whereas this development is promising for the field, oncological risk has become more heterogeneous as a result and this contributes to decreasing utility of MC. (4, 14) In fact, the transplant community has made changes in allocation policy in an effort to establish a more holistic evaluation of patient and tumor risk. Recent examples include the eligibility for exceptional status under the United Network for Organ Sharing, requiring patients undergoing LT for HCC to wait a minimum of 6 months (tumor declaration period) and will soon require an alpha-fetoprotein (AFP) less than 1,000IU/mL before transplantation. (15, 16) However, this is a reactive framework enacted in a piece-wise fashion that is based on interim analyses and not a systematic evaluation of underlying risk determinants.
Most recently, our group established a simple, continuous, risk equation (hazard associated with liver transplantation for hepatocellular carcinoma; HALTHCC), which can be calculated using only preoperatively accessible data and which outperformed all previous metrics, including MC, in a nation-wide experience. (14) One advantage of a continuous score is that it could be easily followed to evaluate both chronological changes in oncological risk as well as response to LRT. This multicenter collaboration aimed to test the hypothesis that the HALTHCC score can serve as a framework through which to observe the LT candidate and their risk across time (while waiting after presentation, peri-LRT changes, etc.) in a heterogeneous and dynamic cohort, including all patients listed for LT for HCC (including dropout patients). Additionally, it might more accurately discriminate post-LT prognosis with particular reference to changes following LRT and could support studies of a new allocation model.
Patients and Methods

StUDy popUlatioN
This multicenter study was conducted from 2002 to 2014 with inclusion criteria defined as adults being listed for first-time LT for a primary or secondary diagnosis of HCC (n = 654). Patients were excluded if they had incidental HCCs (discovered on explant pathology; n = 78) or had an incomplete data set (including patients with fewer than two pre-LT imaging evaluations, given that longitudinal assessment could not occur in those cases; n = 157). The approach at both the Cleveland Clinic Foundation (CCF) and the Massachusetts General Hospital (MGH) is holistic evaluation of all HCC patients at presentation and aggressive downstaging of those patients outside of MC through LRT, including transarterial catheter ablation (TACE), radiofrequency ablation (RFA), and less commonly others (microwaveor cryoablation, external beam/proton radiation, and, in select patients, hepatectomy). (17, 18) Patient selection was decided by a multidisciplinary group at Liver Tumor Board meetings. Management, transplantation, and follow-up were described. (17, 18) Response to LRT was evaluated using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria around 4 weeks post-LRT using the provided guidelines. (13) A control cohort (n = 68) was included to assess natural variation in the HALTHCC score without LRT intervention to more readily attribute changes in HALTHCC post-LRT to LRT and not random fluctuation in the levels of contributing factors. This was compared to 351 patients (n = 201 from CCF and n = 150 from MGH) who underwent LRT while listed. Laboratory data to compute the Model for End-Stage Liver Disease Sodium score (MELD-Na; sodium, creatinine, total bilirubin, international normalized ratio, and AFP) from the date of presentation (median of 377 days before LT; interquartile range [IQR] , 174, 715) through LRT until delisting (LT or dropout) were collected on each patient (Supporting Fig. S1A-D) . In general, 15-25 complete lab dates were collected per patient. This was collated with 2,085 triphasic computed tomography and contrast enhanced magnetic resonance studies (yielding lesion maximal size, number of lesions, viable tumor diameter, and mRECIST response grade for post-LRT studies) to generate HALTHCC data points from presentation through LRT and then delisting (median, 5 complete points; [QR, 4, 7; Supporting Fig. S1 ). Data points were considered to overlap if they were within 1 week of an imaging study, unless intervention (such as LRT) was between those dates. Delisting occurred at either time of LT (n = 309) or dropout (removal for tumor progression or too sick, n = 110). Post-LT follow-up was a median of 1,239 days (IQR, 830, 1,938). This study was approved by the institutional review board at both institutions.
StatiStiCal aNalySiS
The TRIPOD-IV framework was used to transparently report this validation study. (19) Tumor burden score is the hypotenuse between lesion number and lesion size by the Pythagorean theorem. (14) It was previously validated as an equivalent measure to the sum of lesion number and maximal lesion size and superior to total tumor volume. (14) We performed an intentionto-treat analysis (ITT) with ITT-mortality defined as the interval from presentation to either, mortality, dropout, or last follow-up (if censored). (20) Dropout and mortality post-LT were considered as events. In LT patients, overall survival (OS) was defined as the time interval from LT to either mortality or last follow-up (if censored); recurrence was defined similarly. HALTHCC score was previously specified and is calculated using Equation 1: HALTHCC = (1.27 * TBS) + (1.85 * InAFP) + (0.26 * MELD−Na). It is important to note that MELD-Na in this equation refers to the laboratory score for candidates and has no relationship to MELD exception points. HALTHCC was previously validated in the Scientific Registry of Transplant Recipients (SRTR) national cohort and statistically superior against all other preoperatively assessable scores. (14) However, a limited longitudinal analysis (presentation, listing, and pre-delisting) was included for the MORAL, (5) AFP, (8) and Metroticket 2.0.
Cox proportional hazards models and the KaplanMeier (KM) method were used to assess associations with ITT-mortality, OS, and recurrence. The proportional hazards assumption was not violated as assessed through Schoenfeld residuals and the related global test (P = 0.578). Spline analysis was performed in the standard fashion to assess linearity of risk over delta HALTHCC intervals. Postestimation concordance and discrimination were calculated by using receiver operator characteristics (ROC) plots with Harrell's C-index, Akaike information criterion, net reclassification improvement, and integrated discrimination improvement. Discrimination values were also fit to a linear regression to test the hypothesis that they changed over time in the standard fashion. Categorical variables were summarized by counts and percentages and continuous variables by medians and IQRs 25th-75th percentiles. Categorical testing was done using Fisher's exact test for count data. Continuous variables were tested using the Wilcoxon rank-sum or Kruskal Wallis with posthoc Dunn's test, depending on the number of groups. All testing was two-sided and used a 5% level of significance. All analyses were done using STATA software (version 13; StataCorp LP, College Station, TX).
Results
CHaraCteriZatioN oF tHe MiXeD CoHort
Characteristics of this multicenter cohort are described in Table 1 . Control and LRT patients were listed during similar times in our groups' experience. Across both groups, recipients were mostly males (69.1% vs. 74.1%; P = 0.518; with median age of 59 [55, 64] vs. 60 [55, 64] years; P = 0.495) and had a similar background liver disease (P = 0.563), predominantly related to hepatitis C virus (HCV; 61.8% vs. 63.0%). Severity of liver disease at presentation to the transplant center (11 [7, 17] vs. 9 [6, 13] points; P = 0.059) and waiting time on the transplant list (4.8 [1.8, 10.5] vs. 5.3 [2.3, 12.3] months; P = 0.499) was similar between groups. MELD-Na score at most recent pre-delisting labs was greater in the LRT group (14 [8, 22] vs. 11 [7, 16] points; P = 0.016).
Patient characteristics by center were examined to better understand the cohort under examination and are summarized in Supporting Table S1 . Patient characteristics were similar comparing CCF relative to MGH, except a decreased proportion of males (65.2% vs. 86.0%; P < 0.0001), decreased lab MELD-Na at presentation (9 [6, 13] vs. 10 [7, 15] points; P = 0.017) and at pre-delisting (10 [6, 16] vs. 12 [8, 16] points; P = 0.056), decreased waiting time (84 [44, 159] vs. 365 [222, 489] days; P < 0.0001), and generally greater tumor risk at both presentation as measured by MC, tumor number, maximal lesion diameter, and HALTHCC score and at pre-delisting. AFP was statistically insignificant.
In terms of tumor characteristics, there were relatively more differences between controls and the LRT group than between institutions. At presentation, the Laboratory MELD-Na, points at presentation 11 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 9 [6, 13] 0.059
Laboratory MELD-Na, points pre-delisting 14 [8, 22] 11 [7, 16] On the most recent evaluation before delisting, the control group had progressed from presentation whereas the LRT group had regressed or remained stable (Fig. 1A,B) . At pre-delisting, the control group compared to the LRT group had a similar number of MC patients (80.9% vs. 79.2%; P = 0. Fig. S2A ). From presentation to listing to pre-LT evaluation, HALTHCC score had increasing discriminatory value over time (Fig. 1C) . Assessed longitudinally from 0 to 500 pre-delisting days, the utility of HALTHCC increased greatly (0.576 vs. 0.785; P < 0.0001; Fig. 1D ).
MeaSUriNg tHe tUMor reSpoNSe to lrt
Measuring tumor response to LRT may serve as an additional test of tumor biology pre-LT. In this multicenter trial, patients underwent LRT at either the CCF (n = 201) or MGH (n = 150). HALTHCC score was significantly higher at presentation in the CCF cohort as compared to MGH (12.2 [10.2, 14.9] vs. 11.2 [9.1, 14.0]; P = 0.012; Supporting Table S1 ). These scores increased and this difference persisted by the time patients underwent their pre-delisting evaluation (12.6 Table S2 ). In terms of HALTHCC, Fig. 2A demonstrates the change in score post-LRT, which can be quantified as either absolute difference (Fig. 2B ) or relative differences (Fig. 2C) . Risk of ITTmortality was nearly linear, but tumor response was relatively less protective than tumor progression was a risk (comparing slopes from Fig. 2D ). LRT response was a significant factor for survival despite adjustment for pre-LRT HALTHCC score (Table 2 ). Figure 2E ,F demonstrates ITT KM survival estimates as a function of tumor response to LRT for mRECIST and delta HALTHCC, respectively. Both models identified at-risk progressive disease patients whereas delta HALTHCC more clearly elucidates the risk for stable disease versus partial response patients. LRT type also varied significantly by mRECIST response, with patients experiencing a complete response having more often undergone RFA (69.3%) as compared to patients who achieved only partial response (27.5%), stable disease (11.9%), or progressive disease (29.0%; globally, P < 0.0001). There was an inverse association with mRECIST response and TACE (P < 0.0001). Finally, tumor response as measured by HALTHCC identified at-risk patients among mRECIST responders and nonresponders (Table 3; Fig. 2G,H) .
Discussion
This multicenter study extended the utility of HALTHCC by establishing a role for longitudinal assessment of candidate risk, which led to increased contextualization of tumor response to LRT and superior prognostication among increasingly heterogeneous tumor-risk profiles. This work also provides the foundation for a more efficacious allocation scheme that better incorporates the concepts elaborated in the "final rule." Because waiting times have increased nationwide, the problem of tumor progression in candidates with HCC has become more pervasive and the role of bridging therapy to maintain candidates within criteria more pivotal. (14, 19) With increasing penetration of bridging and downstaging LRT comes increasing heterogeneity of oncological risk and decreases in the predictive quality of selection criteria, which were derived in an environment with less LRT. This heterogeneity of post-LRT prognostic risk in MC-in patients may underlie the increasing reports of poor prognostic utility of the current allocation schemes despite relatively strict criteria. Continuous risk modeling enables an assessment of overall response to courses of repetitive LRT. Currently, post-LRT assessment has revolved around the mRECIST criteria, which consider only tumor morphological response. (11) Although mRE-CIST is widely accepted, its utility is limited; complete response and progressive disease generally portend disparate outcomes, partial response and stable disease are poorly discriminated. (12, 22) This study investigated the utility of following tumor risk over time, using a continuous risk score, with particular attention to the value of peri-LRT changes in prognostic risk. This study improves on past work by incorporating an ITT approach including all our centers' LT and dropout patients and comparing our findings to other relevant risk models. Statistical analysis revealed that LRT response assessment using HALTHCC had better prognostic discrimination than other preoperative risk models as well as mRECIST evaluation. Perhaps more important, pre-delisting HALTHCC was shown to have the greatest utility for ITT-mortality, post-LT survival, and recurrence regardless of LRT response. According to these results, a basic principal of organ allocation based on HALTHCC was proposed.
Utility of HALTHCC for predicting both mortality (ITT and post-LT) and recurrence post-LT increased from presentation to listing and to the most recent evaluation before delisting (Fig. 1C,D) . This study confirmed the role of LRT as a bridge to transplant in the largest granular data set to our knowledge, with 2,085 imaging studies over 419 patients. LRT effectively decreased the slope of preoperative prognostic risk consistent with previous studies. Additionally, the data presented argue that risk at presentation is only poorly associated with outcomes ( Fig. 1C ; Supporting  Table S3 ). Importantly, HALTHCC utility was similar to other metrics at presentation and superior at listing and pre-delisting. Whereas this is an intuitive finding if one understands the derivation of this continuous risk metric, it goes against the current practice where the patient is either within MC (and receives full benefit therein) or out (and becomes inactive or delisted pending LRT). Drescher et al. presented an elegant discussion of the value of longitudinal assessment of CA-125 using Bayesian statistical methods to improve sensitivity in ovarian cancer screening. (24) The concept that following an individual's biomarker trend is more informative than single-value cutpoints or even population adjusted cutpoints is not particularly provocative, rather its application to LT for HCC is overdue. Patients present with a particular tumor burden and associated risk set, which is modified according to the aggressiveness of their treatment (highly variable by center for similar patients) and their underlying tumor biology (difficult to assess without longitudinal data). Historically, these additional data may have been only crudely incorporated into the clinical practice as part of an informal assessment of a patient's response. However, with the advent of efficacious LRT and new allocation policies mandating observation, these data are becoming more important. According to our finding, LT should be at first open to most HCC patients and final priority decided through formal and continuous assessment of post-LT risk using the most up-to-date HALTHCC. To further establish the prognostic role of longitudinal changes in continuously measured risk, the prognostic impact of delta HALTHCC score peri-LRT was also investigated.
HALTHCC response to LRT had better prognostic discrimination than mRECIST evaluation, most significantly, use of the continuous score stratified patients within the poorly discriminated mRE-CIST partial response and stable disease grades. This is especially critical given that 48.4% (170 of 351) of our patients fell into the partial response/stable disease grades. LRT assessment by the mRECIST framework has two major drawbacks: (1) mRECIST was not originally designed to evaluate pre-LT risk, and the grades of response were not statistically developed, and (2) the evaluation of mRECIST reflects a single time point post-LRT and does not reflect dynamic oncological changes over the waiting period. Using the mRECIST criteria, past reports were confirmed in this study and patients who had progressive disease following LRT were likely to have worse outcome (ITT-mortality, Fig. 2E ; post-LT survival, Supporting Fig. S3 ). (12, 22) However, mRECIST criteria were poorly sensitive to identifying mortality or recurrence amongst patients with stable disease/partial response/complete response Fig. 2E and Supporting Fig. S4C , respectively). This poor performance would not be surprising considering the above-mentioned background of mRECIST. However, it is especially problematic that the criteria are so widespread, but poorly specify the risk of a majority of patients. In contrast, HALTHCC-based assessment shows a dramatic shift in the rate of complete response/partial response/stable disease and still identifies a similar cohort of PD patients (Table 3) at risk for ITT-mortaltiy, post-LT mortality, and recurrence ( Fig. 2F and Supporting Figs. S3F and S4D, respectively). The most compelling point is that HALTHCC response (partial response/ complete response) versus nonresponse (stable disease/progressive disease) could be used to significantly stratify risk even among patients who had achieved a mRECIST response (Fig. 2G ) and those who failed to respond (Fig. 2H ). These trends persisted for post-LT survival and tumor recurrence (Supporting Figs. S3 and S4, respectively). Thus, HALTHCC could serve as a more useful measure of risk assessment post-LRT. Perhaps more important, HALTHCC could serve as an ever-present risk and treatment effect score in LT. This holistic framework might improve gaps in the current pathway of LT evaluation, listing, and allocation. Finally, this study introduced a proposed model of allocation to undergo future study. The obvious extension of HALTHCC and the evidence supporting pre-LT value as the best predictor is a translation of that score into priority. Currently, tumor/clinical risk in LT candidates with HCC is distributed nearly randomly across transplant priority as exception points are awarded with increasing waiting time on the transplant list (Fig. 3A) . HALTHCC can be transformed into a priority score (40-HALTHCC) to minimize risk of mortality and recurrence at the highest levels of transplant priority. Under the proposed system, a patient would acquire exceptional points inversely related to their tumor risk. SRTR data were used to model waiting time as a function of recipient factors, especially MELD score to estimate the waiting time for the patients in this study under the proposed allocation scheme (Fig. 3B) . In contrast to the current schema, there is a very clear association between tumor risk and waiting time, which may more appropriately balance the HCC cohort's pre-LT mortality benefit with the non-HCC cohorts' reduced risk of post-LT recurrence. A series of 5 simulated patients are illustrated from presentation to transplantation with details of risk, LRT, and subsequent response as well as estimates for waiting time, recurrence risk, and mortality risk under the proposed allocation scheme (Supporting Fig. S5 ). Of course, this new principle requires further modification; however, this foundational concept could easily be adjusted for HCC organ volumes. Moreover, this model could also be modified to reduce regional disparities or be adjusted to disadvantage those patients who have almost no risk of dropout while awaiting LT (perhaps lowest HALTHCC score patients can be more readily identified as appropriate for resection using quantitative methods). As mentioned above, this model can open the opportunity of LT for all HCC patients, with further selection of optimal candidates during the waiting period. The current allocation scheme has been adjusted statistically to target post-LT outcomes using systematic recalibration of exception points and waiting time. However, prognostic discrimination of MC is suboptimal as previously shown (C-index = 0.52-0.55). (14) This low prognostic discrimination suggests that the current allocation scheme wastes an uncertain number of precious donated organs, which would be reduced or prevented with a statistically superior scheme. A transplant society national conference held in 2010 had a general consensus of the need for a calculated, continuous HCC priority score for ranking HCC candidates on the list that would incorporate laboratory MELD, AFP, tumor size, and rate of tumor growth. (25) The comprehensive system presented in HALTHCC is a realized innovation from these goals.
This study has several important limitations to consider and to inform the next step of large, simulation-based studies. This cohort is bicentric and heterogeneous in nature. The two centers see different types of patients in different practice environments. However, it should be noted that a heterogeneous population increases the generalizability of our findings by not limiting our population to those within MC, or with <X# of lesions and beyond MC. We evaluated all patients evaluated and listed at our centers regardless of outcome, greatly strengthening the relevance of our findings. Finally, because mRECIST is the predominant system used in the United States, we did not evaluate World Health Organization or European Association for the Study of the Liver criteria in comparing HALTHCC response criteria.
In conclusion, the current study validated the role of longitudinal assessment of HALTHCC for candidates at presentation through their waiting period. It also established a role for HALTHCC in measuring response to LRT while awaiting LT; even above and beyond the current gold standard, mRECIST. Statistical analyses suggested benefits of introduction of continuous priority scoring for allocation of organs in LT for HCC based on HALTHCC (even compared to other competitor models). Although extensive discussion and consideration are required, continuous risk scoring in LT for HCC may be a key renovation of this field.
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